Stamulumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameStamulumab
Drug Alias Name司达鲁单抗stamulumabumestamulumab司他芦单抗MYO-029 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGrowth/differentiation factor 8 inhibitors
TargetsGrowth/differentiation factor 8
Therapy Area/IndicationsBecker muscular dystrophyMuscular Dystrophy, FacioscapulohumeralMuscular Dystrophies, Limb-Girdle
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth Llc
Active IndicationsN/A
Inactive IndicationsBecker muscular dystrophyMuscular Dystrophy, FacioscapulohumeralMuscular Dystrophies, Limb-Girdle

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG